Pharmaceutical

Risk adjusted net present value: What is the current valuation of ORIC Pharmaceuticals’s ORIC-944?

ORIC-944 is a small molecule commercialized by ORIC Pharmaceuticals, with a leading Phase I program in Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Dec 13, 2024 - 06:00
ORIC-944 is a small molecule commercialized by ORIC Pharmaceuticals, with a leading Phase I program in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Rallybio’s RLY...

Next Article

Risk adjusted net present value: What is the current valuation of Plus Therapeut...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: White House imposes price limits for Regeneron Covid drug; lawmakers push federal agencies to prevent patent abuses

STAT+: Pharmalittle: White House imposes price limits f...

Sep 14, 2023

STAT+: Springworks wins FDA approval for drug to treat desmoid tumors

STAT+: Springworks wins FDA approval for drug to treat ...

Nov 27, 2023

Huawei’s top 10 construction principles for intelligent computing centre facilities

Huawei’s top 10 construction principles for intelligent...

Nov 15, 2024